EBS Q4 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$277M-16.2% YoY

Gross Profit

$169M61.2% margin

Operating Income

-$44M-15.8% margin

Net Income

-$50M-17.9% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.2B

Stockholders' Equity

$649M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$277M	$330M	-16.2%
Gross Profit	$169M	$114M	+48.0%
Operating Income	-$44M	-$55M	+20.8%
Net Income	-$50M	-$67M	+26.1%

Revenue Segments

Product

$249M90%

Contract Development And Manufacturing

$20M7%

Contracts and Grants

$7M2%

Geographic Segments

Services Segment

$20M100%